Cargando…

How Hydroxyurea Alters the Gut Microbiome: A Longitudinal Study Involving Angolan Children with Sickle Cell Anemia

Sickle cell anemia (SCA) is an inherited hematological disorder and a serious global health problem, especially in Sub-Saharan Africa. Although hydroxyurea (HU) is the leading treatment for patients with SCA, its effects on the gut microbiome have not yet been explored. In this context, the aim of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delgadinho, Mariana, Ginete, Catarina, Santos, Brígida, Fernandes, Carolina, Silva, Carina, Miranda, Armandina, de Vasconcelos, Jocelyne Neto, Brito, Miguel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409137/ https://www.ncbi.nlm.nih.gov/pubmed/36012325 http://dx.doi.org/10.3390/ijms23169061

Ejemplares similares

Are Genetic Modifiers the Answer to Different Responses to Hydroxyurea Treatment?—A Pharmacogenetic Study in Sickle Cell Anemia Angolan Children
por: Ginete, Catarina, et al.
Publicado: (2023)

Genotypic Diversity among Angolan Children with Sickle Cell Anemia
por: Delgadinho, Mariana, et al.
Publicado: (2021)

Microbial gut evaluation in an angolan paediatric population with sickle cell disease
por: Delgadinho, Mariana, et al.
Publicado: (2022)

PI-03: THE EFFECT OF HYDROXYUREA IN THE GUT MICROBIOME OF ANGOLAN CHILDREN WITH SICKLE CELL DISEASE
por: M., DELGADINHO, et al.
Publicado: (2022)

5595849 THE GUT MICROBIOME AND HYDROXYUREA EFFECT ON SICKLE CELL DISEASE CHILDREN FROM ANGOLA
por: Brito, M., et al.
Publicado: (2023)

P101: GUT MICROBIOTA IMPACT ON ANGOLAN CHILDREN WITH SICKLE CELL DISEASE
por: Brito, M, et al.
Publicado: (2022)

P-057: GENETIC VARIABILITY AND DISEASE SEVERITY IN A COHORT OF ANGOLAN SICKLE CELL DISEASE PATIENTS
por: M., BRITO, et al.
Publicado: (2022)

Efficacy and safety of pharmacological interventions for managing sickle cell disease in children and adolescents: protocol for a systematic review with network meta-analysis
por: Tonin, Fernanda S, et al.
Publicado: (2023)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

5589865 PRELIMINARY FINDINGS FROM THE FOLLOW-UP OF PREGNANT SICKLE CELL DISEASE PATIENTS IN LUANDA, ANGOLA.
por: Brito, M., et al.
Publicado: (2023)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

5588995 COMPARATIVE EFFICACY AND SAFETY OF PHARMACOLOGICAL INTERVENTIONS FOR SICKLE CELL DISEASE IN CHILDREN AND ADOLESCENTS: A NETWORK META-ANALYSIS
por: Tonin, F.S., et al.
Publicado: (2023)

Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia
por: Silva, Danilo Grunig Humberto, et al.
Publicado: (2013)

Menopause in Brazilian women with sickle cell anemia with and without hydroxyurea therapy
por: Queiroz, Ana Mach, et al.
Publicado: (2021)

Intensive hydroxyurea dosing in very young children with sickle cell anemia
por: Wang, Winfred C., et al.
Publicado: (2023)

Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub‐Saharan Africa: Rationale and Design of the REACH Trial
por: McGann, Patrick T., et al.
Publicado: (2015)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

Influence of βS-globin haplotypes hydroxyurea on tumor necrosis factor-alpha levels in sickle cell anemia
por: Laurentino, Marília Rocha, et al.
Publicado: (2014)

Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia
por: Ghasemi, A, et al.
Publicado: (2014)

From Infancy to Adolescence: Fifteen Years of Continuous Treatment With Hydroxyurea in Sickle Cell Anemia
por: Hankins, Jane S., et al.
Publicado: (2014)

Analysis of oxidative status and biochemical parameters in adult patients with sickle cell anemia treated with hydroxyurea, Ceará, Brazil
por: Teixeira Neto, Paulo Florentino, et al.
Publicado: (2011)

Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial
por: Abdullahi, Shehu U., et al.
Publicado: (2023)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Hydroxyurea treatment is associated with reduced degree of oxidative perturbation in children and adolescents with sickle cell anemia
por: Vinhaes, Caian L., et al.
Publicado: (2020)

Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy
por: Dhar, Arushi, et al.
Publicado: (2021)

Prevalence of major and minor electrocardiographic abnormalities and their relationship with cardiovascular risk factors in Angolans
por: Gonçalves, Mauer A.A., et al.
Publicado: (2022)

Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen
por: Paule, Ines, et al.
Publicado: (2011)

Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients
por: Guarda, Caroline C., et al.
Publicado: (2019)

Effectiveness of Pharmacokinetic-Guided Hydroxyurea Dose Individualization in Patients with Sickle Cell Anemia: A Mini-Review
por: dos Santos Neres, Joelma Santana, et al.
Publicado: (2023)

Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia
por: Rankine-Mullings, Angela, et al.
Publicado: (2023)

Protective effect of flavonoids against reactive oxygen species production in sickle cell anemia patients treated with hydroxyurea
por: Henneberg, Railson, et al.
Publicado: (2013)

Whole Exome Sequencing Identifies Novel Genes for Fetal Hemoglobin Response to Hydroxyurea in Children with Sickle Cell Anemia
por: Sheehan, Vivien A., et al.
Publicado: (2014)

Comment on “Influence of βS-globin haplotypes and hydroxyurea on tumor necrosis factor-alpha levels in sickle cell anemia”
por: de Souza Torres, Lidiane
Publicado: (2014)

Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia
por: Fitzhugh, Courtney D., et al.
Publicado: (2015)

The Effects of Hydroxyurea Therapy on the Six-Minute Walk Distance in Patients with Adult Sickle Cell Anemia: An Echocardiographic Study
por: Garadah, Taysir, et al.
Publicado: (2019)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_8fqc0kk3992oredrq402rtn32f